Brief: Pharmacyte Biotech- On Feb 24, Received Notification Letter From Nasdaq, Co Was No Longer In Compliance With Nasdaq’S Board Independence Rule
01/03/2022 11:50
March 1 (Reuters) - PharmaCyte Biotech Inc PMCB.O :
* PHARMACYTE BIOTECH- ON FEB 24, RECEIVED NOTIFICATION
LETTER FROM
NASDAQ, CO WAS NO LONGER IN COMPLIANCE WITH NASDAQ’S BOARD
INDEPENDENCE RULE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmacyte Biotech
See all newsBrief: Pharmacyte Biotech Inc - Increases Stake In Tnf Pharmaceuticals By $3 Million
Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer